USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CELEK PHARMACEUTICALS, LLC
Address:
119 UPSHIRE CIR
GAITHERSBURG, MD 20878-5215
Phone:
N/A
URL:
N/A
EIN:
126428832
DUNS:
831413419
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $356,837.00 2

Award List:

Developing a Novel Peptide Therapeutic for Interstitial Cystitis/Painful Bladder

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$180,571.00
Agency:
HHS
Principal Investigator:
Graham P. Allaway
Abstract:
DESCRIPTION (provided by applicant): The overall goals of the proposed phase 1 SBIR project are to investigate the in vivo efficacy and mechanism of action of a novel, first-in-class drug candidate for treating interstitial cystitis/painful bladder syndrom e (IC/PBS). IC/PBS is a chronic and… More

TAS::75 0849::TAS TOPIC 255: A TARGETED DRUG FOR NON-MUSCLE INVASIVE BLADDER CANCER

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$176,266.00
Agency:
HHS
Principal Investigator:
Graham Allaway – 301-452-6452
Abstract:
CEL-031 is being developed as a novel, targeted tre8tment for non-mLiscle invasive bladder cancer (NMIBC). Bladder cancer is the 5th most common cancer in the US, with most cases diagnosed 8t the nonmuscle invasive stage. It is the most expensive cancerto treDt on a per patient basis. There is 8… More